Equities research analysts expect OrthoPediatrics Corp. (NASDAQ:KIDS) to announce $24.14 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for OrthoPediatrics’ earnings. The lowest sales estimate is $23.70 million and the highest is $24.59 million. OrthoPediatrics reported sales of $13.59 million during the same quarter last year, which suggests a positive year-over-year growth rate of 77.6%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 4th.
On average, analysts expect that OrthoPediatrics will report full-year sales of $96.02 million for the current financial year, with estimates ranging from $95.44 million to $96.61 million. For the next year, analysts expect that the firm will post sales of $116.62 million, with estimates ranging from $112.09 million to $122.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for OrthoPediatrics.
OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, May 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). OrthoPediatrics had a negative net margin of 34.26% and a negative return on equity of 11.57%.
Several equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of OrthoPediatrics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 11th. Truist raised their target price on shares of OrthoPediatrics from $64.00 to $72.00 in a research note on Friday, May 7th. Truist Securities raised their target price on shares of OrthoPediatrics from $64.00 to $72.00 in a research note on Friday, May 7th. JMP Securities lifted their price objective on shares of OrthoPediatrics from $55.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, May 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $70.00 price objective (up from $62.00) on shares of OrthoPediatrics in a research report on Thursday, May 6th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. OrthoPediatrics presently has an average rating of “Buy” and an average price target of $64.71.
Shares of NASDAQ:KIDS traded up $0.07 during midday trading on Thursday, hitting $56.03. The stock had a trading volume of 67,849 shares, compared to its average volume of 188,835. OrthoPediatrics has a 12 month low of $38.01 and a 12 month high of $64.96. The business’s 50-day simple moving average is $54.31 and its 200-day simple moving average is $48.60. The company has a market cap of $1.10 billion, a P/E ratio of -38.91 and a beta of 0.67.
In other news, Director Terry D. Schlotterback sold 4,700 shares of OrthoPediatrics stock in a transaction on Monday, May 10th. The stock was sold at an average price of $63.03, for a total transaction of $296,241.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President David R. Bailey sold 4,769 shares of OrthoPediatrics stock in a transaction on Monday, March 1st. The stock was sold at an average price of $55.84, for a total value of $266,300.96. Following the sale, the president now directly owns 88,373 shares of the company’s stock, valued at approximately $4,934,748.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,360 shares of company stock valued at $2,389,418. Company insiders own 33.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Sageworth Trust Co acquired a new stake in shares of OrthoPediatrics during the first quarter worth $46,000. Group One Trading L.P. acquired a new position in OrthoPediatrics in the fourth quarter valued at about $58,000. Maverick Capital Ltd. acquired a new position in OrthoPediatrics in the first quarter valued at about $65,000. SG Americas Securities LLC acquired a new position in OrthoPediatrics in the first quarter valued at about $139,000. Finally, Jane Street Group LLC acquired a new position in OrthoPediatrics in the fourth quarter valued at about $201,000. 71.74% of the stock is owned by institutional investors.
OrthoPediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
See Also: LIBOR
Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
